Your browser doesn't support javascript.
loading
A comprehensive evaluation of regression-based drug responsiveness prediction models, using cell viability inhibitory concentrations (IC50 values).
Park, Aron; Joo, Minjae; Kim, Kyungdoc; Son, Won-Joon; Lim, GyuTae; Lee, Jinhyuk; Kim, Jung Ho; Lee, Dae Ho; Nam, Seungyoon.
Afiliação
  • Park A; Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon 21999, Korea.
  • Joo M; Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon 21999, Korea.
  • Kim K; VUNO Inc., Seoul 06541, Korea.
  • Son WJ; Samsung Advanced Institute of Technology, Samsung Electronics, Suwon, Gyeonggi-do 16678, Korea.
  • Lim G; Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.
  • Lee J; Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.
  • Kim JH; Department of Bioinformatics, University of Sciences and Technology, Daejeon 34113, Korea.
  • Lee DH; Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon 21565, Korea.
  • Nam S; Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon 21999, Korea.
Bioinformatics ; 38(10): 2810-2817, 2022 05 13.
Article em En | MEDLINE | ID: mdl-35561188
MOTIVATION: Predicting drug response is critical for precision medicine. Diverse methods have predicted drug responsiveness, as measured by the half-maximal drug inhibitory concentration (IC50), in cultured cells. Although IC50s are continuous, traditional prediction models have dealt mainly with binary classification of responsiveness. However, since there are few regression-based IC50 predictions, comprehensive evaluations of regression-based IC50 prediction models, including machine learning (ML) and deep learning (DL), for diverse data types and dataset sizes, have not been addressed. RESULTS: Here, we constructed 11 input data settings, including multi-omics settings, with varying dataset sizes, then evaluated the performance of regression-based ML and DL models to predict IC50s. DL models considered two convolutional neural network architectures: CDRScan and residual neural network (ResNet). ResNet was introduced in regression-based DL models for predicting drug response for the first time. As a result, DL models performed better than ML models in all the settings. Also, ResNet performed better than or comparable to CDRScan and ML models in all settings. AVAILABILITY AND IMPLEMENTATION: The data underlying this article are available in GitHub at https://github.com/labnams/IC50evaluation. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Redes Neurais de Computação / Aprendizado de Máquina Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Redes Neurais de Computação / Aprendizado de Máquina Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article